Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Lihong Bai"'
Publikováno v:
PeerJ, Vol 11, p e16581 (2023)
Objective To investigate the effect of the kinase inhibitor AT9283 on Burkitt lymphoma (BL) cells and elucidate the underlying mechanisms. Methods The effect of AT9283 on the proliferation of BL cell lines was tested using the MTT assay. Apoptosis an
Externí odkaz:
https://doaj.org/article/d30971e35acc4342becd736116337c8b
Autor:
Huixia Li, Yifan Zheng, Peihang Xu, Zimu Li, Yukun Kuang, Xiaoqing Feng, Junhao He, Jia Li, Xiao Chen, Lihong Bai, Ke-Jing Tang
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Importance: Checkpoint inhibitor pneumonitis (CIP) is a rare but serious adverse event that may impact treatment decisions. However, there is limited information comparing CIP risks between immune checkpoint inhibitor (ICI) monotherapy and combinatio
Externí odkaz:
https://doaj.org/article/bed0998adab8404db181db6f4c4c277d
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-7 (2020)
Abstract Background According to the proportion of glandular and squamous pathological components, adenosquamous carcinoma (ASC) could be divided into adenocarcinoma (AC) and squamous cell carcinoma (SCC) predominant subtypes. Due to its rarity, no s
Externí odkaz:
https://doaj.org/article/51d631526c3b41c990fa985aba19b793
Autor:
Xubin Liu, Hanyu Ma, Lingyan Fei, Mengjie Jiang, Meng Xia, Lihong Bai, Xufang Pi, Shangwu Chen, Li Yu
Publikováno v:
Infectious Agents and Cancer, Vol 15, Iss 1, Pp 1-10 (2020)
Abstract Cervical cancer is the fourth most common malignant tumor in women worldwide. The persistent infection of high-risk Human Papillomavirus (hrHPV) is considered to be the primary cause of this disease. As an innate immune receptor, the nucleot
Externí odkaz:
https://doaj.org/article/a7c2c7ba27e946b79432683d3780b5bf
Publikováno v:
Biocell; 2024, Vol. 48 Issue 4, p623-637, 15p
Publikováno v:
International Journal of General Medicine
Shan Lin,* Wanmei He,* Zixuan Hu, Lihong Bai, Mian Zeng Department of Medical Intensive Care Unit, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, People’s Republic of China*These authors contributed equally to this wor
Autor:
Shangwu Chen, Meng Xia, Mengjie Jiang, Lihong Bai, Lingyan Fei, Xubin Liu, Xufang Pi, Li Yu, Hanyu Ma
Publikováno v:
Infectious Agents and Cancer, Vol 15, Iss 1, Pp 1-10 (2020)
Infectious Agents and Cancer
Infectious Agents and Cancer
Cervical cancer is the fourth most common malignant tumor in women worldwide. The persistent infection of high-risk Human Papillomavirus (hrHPV) is considered to be the primary cause of this disease. As an innate immune receptor, the nucleotide-bindi
Autor:
Zunfu Ke, Peihang Xu, Jiyu Wang, Lihong Bai, Xue Sun, Huixia Li, Yifan Zheng, RunJing Gan, Kejing Tang, Yukun Kuang, Zimu Li
Publikováno v:
Ann Transl Med
Osimertinib has efficacy superior to that of standard epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) for the first-line treatment of patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC). However, patients t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98c37135c88ce8b60a15041c9e444677
https://europepmc.org/articles/PMC8422132/
https://europepmc.org/articles/PMC8422132/
Background At present, there have been studies showing a correlation between sex differences and prognosis. Nevertheless, the evidence of short- and long-term survival of sex-based differences among critically ill patients with sepsis is still limite
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9fd9eb9881a759c78e08565e0637cd78
https://doi.org/10.21203/rs.3.rs-41722/v1
https://doi.org/10.21203/rs.3.rs-41722/v1
Publikováno v:
BMC Cancer
BMC Cancer, Vol 20, Iss 1, Pp 1-7 (2020)
BMC Cancer, Vol 20, Iss 1, Pp 1-7 (2020)
Background According to the proportion of glandular and squamous pathological components, adenosquamous carcinoma (ASC) could be divided into adenocarcinoma (AC) and squamous cell carcinoma (SCC) predominant subtypes. Due to its rarity, no study inve